Xiaojuan Song

发表

Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant.

Zheng-chao Tu, Zhen Wang, Zhengqiu Li, 2022, Journal of medicinal chemistry.

Identification of U937JAK3-M511I Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor

Zheng-chao Tu, Ke Ding, Zhang Zhang, 2022, Frontiers in Oncology.

Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.

S. Xiang, Xiaoyun Lu, Zheng-chao Tu, 2022, Journal of medicinal chemistry.

Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

J. Smaill, Yongheng Chen, Xiaoyun Lu, 2021, ACS medicinal chemistry letters.

1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions.

Zheng-chao Tu, Zhen Wang, Ke Ding, 2022, European journal of medicinal chemistry.

JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo

Xiaoyun Lu, Zheng-chao Tu, Ke Ding, 2022, Molecules.

Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.

Zheng-chao Tu, Zhang Zhang, L. Qu, 2022, Journal of medicinal chemistry.

Vesicle formation between single-chained cationic surfactant and plasmid DNA and its application in cell transfection

J. Ding, Xia Guo, Xiaojuan Song, 2014, Colloid and Polymer Science.

Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.

Zheng-chao Tu, Ke Ding, Zhang Zhang, 2022, Journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors.

J. Smaill, Zheng-chao Tu, A. Patterson, 2022, Journal of medicinal chemistry.

GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo

Zheng-chao Tu, K. Ding, Zhang Zhang, 2021, Cancer medicine.

Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design.

Yongheng Chen, Zheng-chao Tu, Ke Ding, 2021, Bioorganic & medicinal chemistry.

Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.

S. Xiang, Zheng-chao Tu, Ke Ding, 2022, European journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.

J. Smaill, Yongheng Chen, Xiaoyun Lu, 2022, Journal of medicinal chemistry.

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.

J. Smaill, A. Patterson, Xiaojuan Chen, 2024, Journal of medicinal chemistry.

Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.

Ke Ding, Zhang Zhang, Zhi-Min Zhang, 2023, Journal of medicinal chemistry.

Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway

W. Ye, Zheng-chao Tu, Dongmei Zhang, 2023, International journal of biological sciences.

Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations.

Zhang Zhang, Zhi-Min Zhang, Yang Zhou, 2024, ACS pharmacology & translational science.